Abstract | PURPOSE: PATIENTS AND METHODS: Eligible patients were women aged ≤40 years who were HSCT candidates, were premenopausal, and had both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels ≤20 IU/L. Two 22.5-mg leuprolide doses were delivered in 3-month depot i.m. injections, the first within 2 months before HSCT. Patients were monitored for menstruation return, and ovarian function tests (FSH, LH, and estradiol) were done every 2 months starting 90 days after the last leuprolide dose. RESULTS: Sixty eligible patients were enrolled, 59 underwent HSCT, and 44 were evaluable (median age, 25 years; median follow-up, 355 days). Only seven of 44 patients (16%) regained ovarian function. Of the 33 who received myeloablative regimens, six (18%) regained ovarian function. However, among the 11 who received nonmyeloablative regimens, only one (9%) regained ovarian function (p = .66). CONCLUSION:
Leuprolide did not preserve ovarian function in patients who underwent HSCT using either myeloablative or nonmyeloablative regimens. Other measures that protect ovarian function need to be investigated.
|
Authors | Yee Chung Cheng, Mariko Takagi, Andrea Milbourne, Richard E Champlin, Naoto T Ueno |
Journal | The oncologist
(Oncologist)
Vol. 17
Issue 2
Pg. 233-8
( 2012)
ISSN: 1549-490X [Electronic] England |
PMID | 22282904
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Leuprolide
(adverse effects, therapeutic use)
- Ovary
(drug effects, physiopathology)
- Primary Ovarian Insufficiency
(epidemiology, prevention & control)
|